CRDF vs. VIR, AVXL, NUVB, QURE, IMNM, AVBP, TRVI, PHAR, DAWN, and DNTH
Should you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Vir Biotechnology (VIR), Anavex Life Sciences (AVXL), Nuvation Bio (NUVB), uniQure (QURE), Immunome (IMNM), ArriVent BioPharma (AVBP), Trevi Therapeutics (TRVI), Pharming Group (PHAR), Day One Biopharmaceuticals (DAWN), and Dianthus Therapeutics (DNTH). These companies are all part of the "pharmaceutical products" industry.
Cardiff Oncology vs.
Cardiff Oncology (NASDAQ:CRDF) and Vir Biotechnology (NASDAQ:VIR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings, valuation and community ranking.
16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 7.7% of Cardiff Oncology shares are owned by insiders. Comparatively, 15.6% of Vir Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Cardiff Oncology has higher earnings, but lower revenue than Vir Biotechnology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.
In the previous week, Vir Biotechnology had 6 more articles in the media than Cardiff Oncology. MarketBeat recorded 8 mentions for Vir Biotechnology and 2 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 1.58 beat Vir Biotechnology's score of 1.14 indicating that Cardiff Oncology is being referred to more favorably in the media.
Vir Biotechnology received 15 more outperform votes than Cardiff Oncology when rated by MarketBeat users. However, 65.15% of users gave Cardiff Oncology an outperform vote while only 56.86% of users gave Vir Biotechnology an outperform vote.
Vir Biotechnology has a net margin of -678.40% compared to Cardiff Oncology's net margin of -6,238.17%. Vir Biotechnology's return on equity of -36.71% beat Cardiff Oncology's return on equity.
Cardiff Oncology currently has a consensus target price of $12.00, indicating a potential upside of 315.94%. Vir Biotechnology has a consensus target price of $32.86, indicating a potential upside of 630.97%. Given Vir Biotechnology's higher probable upside, analysts plainly believe Vir Biotechnology is more favorable than Cardiff Oncology.
Cardiff Oncology has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500.
Summary
Vir Biotechnology beats Cardiff Oncology on 11 of the 18 factors compared between the two stocks.
Get Cardiff Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiff Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:CRDF) was last updated on 5/21/2025 by MarketBeat.com Staff
Buy CRDF Stock Free CRDF Stock Alerts